Research programme: Rho kinase inhibitors - Devgen
Latest Information Update: 11 Jul 2008
At a glance
- Originator Devgen
- Mechanism of Action Rho-associated kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Retinitis pigmentosa
Most Recent Events
- 29 Nov 2005 Preclinical trials in Eye disorders in Belgium (unspecified route)